How Is Receptor Activator of Nuclear Factor-κβ/Receptor Activator of Nuclear Factor-κβ Ligand Targeting Ranked as an Immuno-Oncology Target for NSCLC: a Pathway Unclear as yet?

J Thorac Oncol. 2020 Oct;15(10):1561-1564. doi: 10.1016/j.jtho.2020.07.011.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Humans
  • Ligands
  • Lung Neoplasms* / drug therapy
  • NF-kappa B
  • Osteoprotegerin
  • RANK Ligand
  • Receptors, Cytoplasmic and Nuclear

Substances

  • Ligands
  • NF-kappa B
  • Osteoprotegerin
  • RANK Ligand
  • Receptors, Cytoplasmic and Nuclear